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Abstract 
The objective of this study is to evaluate angiogenic effects induced by biodegradable gelatin hydrogel 
granules incorporating mixed platelet-rich plasma (PRP) growth factor mixture (PGFM) and bFGF. The 
PRP was prepared by a double-spinning technique of animal bloods isolated, followed by the treatment 
with different concentrations of calcium chloride (CaCl2) solution. The CaCl2 solution treatment activated 
the platelets of PRP to allow releasing various growth factors, such as platelet-derived growth factor 
(PDGF)-BB, vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β1, and 
epithelial growth factor (EGF). When determined in the PRP treated by different CaCl2 solutions, the high 
amount of representative platelet growth factor, PDGF-BB, VEGF, EGF, and TGF-β1 were detected in 
the CaCl2 concentrations of 1, 2, and 4 wt% compared with higher or lower ones. The PRP treated was 
impregnated into gelatin hydrogels granules freeze-dried at 37 ℃ for 1 hr, and then the percentage of 
PGFM desorbed from the gelatin hydrogel granules was evaluated. The percent PDGF-BB, VEGF, EGF, 
and TGF-β1 desorbed tended to decrease with the decreased CaCl2 concentration. Taken together, the 
CaCl2 concentration to activate PRP for PGFM release was fixed at 2 wt%. In vitro release tests 
demonstrated that the PGFM was released from the gelatin hydrogels granules with time. For the gelatin 
hydrogels incorporating PGFM and bFGF, the time profile of PDGF-BB or bFGF release was in good 
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correspondence with that of gelatin hydrogel degradation. The gelatin hydrogels granules incorporating 
mixed PGFM and bFGF were prepared and intramuscularly injected to a leg ischemia model of mice to 
evaluate the angiogenic effects in terms of histological and laser Doppler perfusion imaging (LDPI) 
examinations. As controls, the hydrogel granules incorporating bFGF, PGFM, and platelet-poor plasma 
(PPP) were used for the angiogenic evaluation. The number of blood vessels newly formed and the 
percentage of α-SMA-positive cells increased around ischemic sites injected with the gelatin hydrogel 
granules incorporating mixed PGFM and bFGF, in marked contrast to other control groups. The blood 
re-perfusion level of ischemic tissues was enhanced by the hydrogel granules incorporating mixed PGFM 
and bFGF, whereas no enhancement was observed for other groups. It is concluded that the dual release 
system of PGFM and bFGF from gelatin hydrogel granules is promising to enhance angiogenic effects. 
 
Keywords 
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Introduction 
Several treatments for therapeutic angiogenesis have been reported to demonstrate their 
potentials experimentally and clinically. Some clinical trials of gene therapy and bone marrow cells 
transplantation have been being carried out. On the other hand, the biosafety of genetic materials is not 
always confirmed [1-3]. In addition, the invasiveness to harvest bone marrow cells and the insufficient 
scientific knowledge and the related technology for bone marrow cells may be potential risks for cell 
therapy [4, 5]. Another choice is to make use of growth factor proteins, which enable cells to naturally 
induce their biological potentials for natural angiogenesis. If the growth factor can be used in vivo with 
the biological activity remaining, the growth factor-induced angiogenesis will be realistic. 
Drug delivery system (DDS) is one of the practically possible technologies to positively 
modify the in vivo biological activity of growth factors. Biodegradable gelatin hydrogels have been 
designed and prepared for the controlled release of bioactive basic fibroblast growth factor  (bFGF) [6], 
transforming growth factor (TGF)-β1 [7], platelet-derived growth factor (PDGF)-BB [8], bone 
morphogenetic protein (BMP)-2 [9-11], and hepatocyte growth factor (HGF) [12, 13]. For example, 
bFGF could be released from the gelatin hydrogels to demonstrate the therapeutic potential of 
angiogenesis in the animal models of ischemic legs and hearts or the angiogenesis-induced enhancement 
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of therapeutic efficacy of cell transplantation of cells [14-21]. In addition, a clinical trial has been started 
to confirm the safety and feasibility of bFGF release from gelatin hydrogels for patients with clinical limb 
ischemia of intractable disease [22]. 
 Platelet-rich plasma (PRP) is a source of autologous growth factors, including PDGF, 
vascular endothelial growth factor (VEGF), TGF-β1, and epithelial growth factor (EGF). Autologous PRP 
has been clinically used in a wide variety of surgical treatments for soft and hard tissues [23], such as the 
intractable wound [24], calvaria [25], or maxillofacial bone defects [26], cosmetic surgery [27, 28], spine 
literature [29], and neovascularization [30]. The platelet growth factors could be also released from the 
gelatin hydrogels to demonstrate their enhanced activity to induce angiogenesis, or the regeneration of 
knee meniscus [31, 32], intervertebral disc [33-35], and bone tissues [25, 36].  
In this study, mixed PRP growth factor mixture (PGFM) and bFGF were incorporated into 
the gelatin hydrogels for the multiple releases and the angiogenic effect was evaluated comparing with 
the release of either PGFM or bFGF from the hydrogels. We have been reported that neovascularization 
can be induced with controlled release of bFGF from gelatin hydrogel. The therapeutic neovasculariation 
generally involve both microvascular and macrovascular processes. At the microvasculatory level, 
angiogenesis is defined as the sprouting and growth of capillaries, which, however, regress after cessation 
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of bFGF stimulation if pericytes are not recruited properly. Therefore, the stabilization of capillary 
networks newly created by mural cells (pericytes), known to be recruited by PDGF-BB, is essential for 
therapeutic neovascularization [37]. The process of capillaries maturation needs the recruitment of mural 
cells mediated by PDGF-BB [37, 38]. Taken together, in this study, we tried the multiple controlled 
release of PGFM and bFGF from the gelatin hydrogel to investigate the maturation of blood vessels 
newly formed in a murine model of hind limb ischemia. Following the intramuscular injection of gelatin 
hydrogel granules incorporating mixed PGFM and bFGF into a ischemia model animal. The in vivo 
angiogenesis was evaluated in terms of histological and laser Doppler perfusion imaging examinations. 
The CaCl2 treatment condition of PRP to allow to release platelet growth factors was optimized based on 
the amount of growth factor released and the release pattern from the hydrogels granules. We examine the 
time profile of representative platelet growth factors from the hydrogel granules comparing with that of 
hydrogel degradation.
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Materials and methods 
Preparation of gelatin hydrogel granules 
The gelatin sample of low endotoxin (beMatrix® Gelatin LS-H) with an isoelectric point (IEP) of 5.0, 
isolated by an alkaline process from the porcine skin, was kindly supplied from Nitta Gelatin Inc., Osaka, 
Japan. Biodegradable gelatin hydrogel granules were prepared by the glutaraldehyde (GA, Wako Pure 
Chemical Industries, Osaka, Japan) cross-linking of gelatin aqueous solution [6, 10, 11]. Briefly, after 
mixing 80 µl of aqueous GA solution (25 wt%) with 40 g of aqueous gelatin solution (5 wt%) preheated 
at 40 ℃, the mixed aqueous solution was cast into a polystyrene dish (127.8 × 85.5 mm2, Thermo Fisher 
Scientific Inc., MA, USA), followed by leaving for 12 hr at 4 ℃ to allow the chemical cross-linking of 
gelatin. The resulting hydrogel sheets were then placed in 100 mM glycine aqueous solution (1 ℓ), 
followed by agitation at room temperature for 1 hr to block the residual aldehyde groups of unreacted GA. 
The cross-linked hydrogel sheets were twice washed with double-distilled water (DDW). After washing, 
they were homogenized with Polytron PT-13000DM system (Central Scientific Commerce, Inc., Tokyo, 
Japan) and separated by sieves to obtain gelatin hydrogel granules at the diameter ranging from 32 to 52 
µm in the DDW-swollen state. Thereafter, the hydrogel granules were freeze-dried, and sterilized with 
ethylene oxide gas. The water content of gelatin hydrogel granules (the weight ratio of water present in 
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the hydrogel to the wet hydrogel) was 96 wt%, when calculated from the hydrogel weight before and after 
swelling in phosphate-buffered saline solution (PBS, pH 7.4) for 24 hr at 37 ℃. 
In vitro degradation assay 
 To evaluate the pattern of hydrogel degradation, the gelatin hydrogel granules were agitated 
in two types of degradation solution (1 ml), which is PBS with or without 10 µg/ml of 
collagenase (collagenase 1A, Nitta Gelatin Inc., Osaka, Japan) at 37 °C. At different time intervals, the 
solution supernatant was removed and replaced with the same volume of fresh PBS solution with or 
without collagenase. The gelatin concentration in each supernatant was determined by optical density 
(OD) measurement at 260 nm by spectrometer (DU800, Beckman Coulter, CA, USA) to evaluate the 
time profile of hydrogel degradation. Experiment was performed independently for 3 samples at every 
sampling time. 
 
Preparation of PRP and growth factors detection 
BALB/c mice (8 weeks old; Shimizu Laboratory Animal Supply, Kyoto, Japan) were used. 
All animal experiments were approved by Kyoto University Committee for Animal Experimentation. 
Briefly, 15 mice were anesthetized by the intraperitoneal injection of pentobarbital (somnopentyl, 
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Kyoritsu Seiyaku, Tokyo, Japan) at a dose of 0.65 mg/kg body weights. PRP was prepared with a 
platelet-rich plasma kit (JP200; Japan Paramedic Co., Ltd, Tokyo, Japan) according to the method 
reported [39-41]. Briefly, animal bloods (10 ml) were collected into tubes containing acid-citrate-dextrose 
solution formula A (1:4 vol/vol) anticoagulant and centrifuged for 7 min at 450 ×G and 4 ℃. Next, the 
yellow plasma with the buffy coat was carefully transferred into a BD Vacutainer® tube (Becton, 
Dickinson and Company, NJ, USA), and then centrifuged for 5 min at 1600 ×G and 4 ℃. The platelet 
pellet was collected and the thrombolytic pellet in 1.0 ml of plasma was used as PRP while the 
supernatant was done for platelet-poor plasma (PPP). Before and after the PRP preparation, an aliquot 
was taken out to count the number of platelets. The density of platelets in the PRP prepared was increased 
by a factor of 5 when compared with that of the original blood. 
To activate PRP for the growth factors release, the PRP prepared was mixed with CaCl2 
solution at concentrations of 0.4, 0.6, 0.8, 1, 2, 4, and 10 wt% at the vol/vol ratio of 7:1, followed by 
leaving for 1 hr at 37 ℃. As controls, PRP was treated with mixed 2 wt% CaCl2 and thrombin solution or 
the conventional freeze-and thaw method [42-44]. Briefly, PRP was frozen by liquid nitrogen for 1 min, 
and then rapidly thaw at 25 ℃. The process was repeated 3 times. 
 The amount of growth factors, such as PDGF-BB, VEGF, EGF, and TGF-β1, released was 
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determined with Quantikine® enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, MN, 
USA), respectively. For TGF-β1 ELISA, the samples were first treated with acid to lower the pH to 2.0 to 
denature latency-associated peptide to allow the detection of active TGF-β1. The supernatant was adjusted 




Evaluation of PDGF-BB desorption from gelatin hydrogel granules incorporating PGFM 
 To evaluate the extent of platelet growth factors impregnated into the gelatin hydrogel 
granules, the amount of growth factors desorbed from gelatin hydrogel granules incorporating PGFM 
with or without CaCl2 treatment. The PRP was incubated with CaCl2 solution at different Ca2+ 
concentration for 1 hr at 37 ℃ or treated with the freeze-and-thaw for 3 times. Then, 100 µl of treated- 
and non-treated-PRP was impregnated into 10 mg of freeze-dried gelatin hydrogel granules for 1 hr at 
37 ℃. The gelatin hydrogel granules incorporating PGFM were placed in 1 ml of PBS, and incubate for 3 
hr at 37℃. The amount of growth factors in each PBS sample was determined by the ELISA similarly. 
The percent adsorption of growth factors to gelatin hydrogel granules was calculated by the following 
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formula.  
Percent adsorption = 100 – (the amount of desorbed growth factor / the amount of impregnated growth 
factor ×100). 
The experiment was done independently three times for each granule. 
 
Preparation of gelatin hydrogel granules incorporating mixed PRP treated and bFGF 
 An aqueous solution of human recombinant bFGF with an IEP of 9.6 (10 mg/ml) was kindly 
supplied by Kaken Pharmaceutical (Tokyo, Japan). The original bFGF solution was diluted with 
physiological saline solution (Otsuka pharmaceutical Co., Ltd. Tokyo, Japan) to give the solution 
concentration of 10 mg/ml. The aqueous solution containing 100 µg of bFGF (10 µl) and 100 µl of 
PGFM were dropped onto a freeze-dried gelatin hydrogel granule for impregnation of PGFM and bFGF 
into the granule. The bFGF and PGFM solutions were completely sorbed into the hydrogel granule by 
swelling at 37 ℃ for 1 hr, because the solution volume was less than theoretically required for the 
equilibrated swelling of hydrogels. Similarly, empty gelatin hydrogels without bFGF were prepared by 
adding PBS as the solution. 
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Release test of bFGF from gelatin hydrogel granules incorporating mixed PGFM and bFGF 
 To evaluate the bFGF release from the gelatin hydrogel granules incorporating mixed PGFM 
and bFGF, the gelatin hydrogels incorporating mixed PGFM and RI labeled-bFGF were incubated in two 
types of release solution (1 ml), which are PBS with and without 10 µg/ml of collagenase at 37 °C. After 
6 hr incubation in PBS, there was a change from PBS to PBS with collagenase. At different time intervals, 
the solution supernatant was removed and replaced with the same volume of fresh PBS solution with or 
without collagenase. In this experiment, the PRP was treated with 2 wt% CaCl2 solution for platelet 
activation, and bFGF was labeled with 125I.  
Basic FGF was radioiodinated with chloramine-T according to the method described by 
Greenwood et al. [45]. Briefly, 5 µl of Na125I was added to 200 µl of 0.5 mg/ml bFGF solution in 0.5 M 
potassium PBS (pH 7.5) containing 0.5 M sodium chloride. Then 0.2 mg/ml of chloramine-T in 0.5 M 
potassium PBS (pH 7.5) containing 0.5 M sodium chloride (100 µl) was added to the solution mixture. 
After agitation at room temperature for 2 min, 100 µl solution containing 0.4 mg of sodium metabisulfate 
was added to the reaction solution to stop the radioiodination. The reaction mixture was passed through 
an anionic-exchange column to remove the uncoupled, free 125I molecules from the 125I-labeled bFGF.  
The mixture of the aqueous solution containing 100 µg of 125I labeled-bFGF (10 µl) and 100 
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µl of PGFM was impregnated into 10 mg of freeze-dried gelatin hydrogel granules for 1 hr at 37 ℃. The 
supernatant was sampled at scheduled times and the amount of bFGF in each supernatant samples were 
determined by the γ-counter. The experiment was done independently three times for each granule. 
 
Release test of PDGF-BB from gelatin hydrogel granules incorporating PGFM 
 To evaluate the platelet PDGF-BB release from the gelatin hydrogel granules incorporating 
PGFM, the gelatin hydrogels incorporating PGFM were incubated in two types of release solution (1 ml), 
which are PBS with and without 10 µg/ml of collagenase at 37 °C. After 12 hr incubation in PBS, there 
was a change from PBS to PBS with collagenase. At different time intervals, the solution supernatant was 
removed and replaced with the same volume of fresh PBS solution with or without collagenase. In this 
experiment, the PRP was treated with 2 wt% CaCl2 solution for platelet activation, and 100 µl of treated 
PRP was impregnated into 10 mg of freeze-dried gelatin hydrogel granules for 1 hr at 37 ℃. The 
supernatant was sampled at scheduled times and the amount of PDGF-BB in each supernatant samples 




In vivo experiments 
 Hind limb ischemia was created in 8-week-old male BALB/c mice. Briefly, after the mice 
were anesthetized by an intraperitoneal pentobarbital (0.65 mg/kg) injection, the right groin area was 
shaved. The entire right saphenous artery and vein, right external iliac artery and vein, and deep femoral 
and circumflex arteries and vein were ligated, cut, and excised to obtain a murine model of severe hind 
limb ischemia. The BALB/c mice treated were randomly classified to 6 groups (n=10 per groups): 
hydrogel granules incorporating mixed PGFM and bFGF (PGFM + bFGF), gelatin hydrogel granules 
incorporating either PGFM or bFGF (PGFM or bFGF), gelatin hydrogel granules incorporating PPP 
(PPP), no-treatment (NT), and PGFM- and bFGF-free PBS (PBS). All drugs were homogeneously 
injected into 5 sites in the thigh muscle of mouse ischemic hind limb by using a 27-gauge needle. 
 The animals were re-anesthetized by an intraperitoneal injection of pentbarbital (0.65 mg/kg) 
1 wk after treatment, and the following measurements were performed to evaluate the in vivo 
angiogenesis. Each experiment was done three times independently otherwise mentioned. 
 
Hind limb Blood perfusion 
 Hind limb blood perfusion was assessed by using a laser Doppler blood perfusion image 
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(LDPI) analyzer (moorLDITM, Moor Instruments, Deven, UK) 1 wk after treatment [14]. To evaluate the 
influence of surgical procedure on the blood flow, the blood perfusion of normal hind limb and treated 
one were measured with LDPI. To minimize external influence, such as light and temperature, the 
perfusion result was expressed as the LDPI index which is the ratio of the blood perfusion in the right 
(ischemic) limb to that in the left (non-ischemic) limb of the same mouse [14, 18, 46]. The blood flow 
was measured in the site of vascular resection. 
 
Histological examination 
 The specimens of muscular tissues were fixed with 4 wt% paraformaldehyde (PFA) in 0.1 M 
phosphate-buffered solution for overnight at 4 ℃ and decalcified with Plank−Rychlo’s solution overnight 
at room temperature. After decalcification, the samples were embedded in paraffin. Each specimen was 
cut into slices of the thigh, 4 µm thick of cross section. For histological analysis, the section was stained 
with hematoxylin and eosin (HE) dyes, the number of blood vessels newly formed in the thigh was 
counted in a blind fashion. The number ratio of blood vessels newly formed in the right (ischemic) limb 




 The animals were re-anesthetized by an intraperitoneal injection of pentbarbital (0.65 mg/kg) 
1 week after treatment, and the mice were perfusion-fixed with 4 wt% PFA solution. The ischemic thigh 
was decalcified and embedded in paraffin. Paraffin sections (5 µm thickness) of tissues were stained with 
a mouse monoclonal anti-α-smooth muscle actin antibody (α−SMA; Sigma-Aldrich Japan K.K., Tokyo, 
Japan). From each mouse, all fields on tissue sections were photographed with a digital camera (Olympus, 
Tokyo, Japan). The number of α−SMA (vascular smooth muscle marker)-positive vessels was counted in 
a blind fashion. The number of blood vessels was counted for HE staining section. The percentage of 
number of α−SMA-positive blood vessels to that of total blood vessels was calculated. Each experiment 
was done three times independently. 
 
Statistical analysis 
 All the statistical data were expressed as the mean ± standard error of the mean. The data 
were analyzed by ANOVA to determine the statistical significance between the two mean values. The p 
value less than 0.05 were considered to be significant. 
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Results 
CaCl2 treatment of PRP for the release of platelet growth factors 
 Table 1 shows the concentration of various growth factors released from PRP after the 
freeze-and-thaw treatment. The treatment activated the platelet of PRP to release various growth factors. 
Based on the profile of growth factors released, PDGF-BB, VEGF, EGF, and TGF-b1 were selected as the 
representative platelet growth factor because of the highest amount and the activity to enhance the 
maturation of blood vessels newly formed [38, 47-53].  
 Figure 1 shows the concentration of PDGF-BB released from PRP after the CaCl2 treatment. Upon 
treating with 0.8, 1, 2, and 4 wt% of CaCl2 solution, the concentration of PDGF-BB in the soluble 
fraction of PRP was significantly high compared with that of non-treated PRP. On the other hand, the 
treatment of 10 wt% CaCl2 solution did not increase the PDGF-BB amount. The concentration of EGF in 
the soluble fraction of PRP was significantly high compared with the non-treated PRP and the 10 wt% 
CaCl2 solution treated PRP (Figure 2A). The amount of VEGF extracted from PRP was higher in PRP 
treated with CaCl2 compared with that of non-treatment (Figure 2B). In this study, PDGF was noted 
because it has on ability to enhance the maturation of blood vessels. In addition, PDGF is one of the main 
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factors present in PRP. On the contrary, the amount of TGF-β1 in PRP treated with 1, 2, and 4 wt% CaCl2 
was higher than that of 10 wt% CaCl2 treated PRP, although it was not significant (Figure 2C). 
 
 
Adsorption of growth factors to gelatin hydrogel granules incorporating PGFM and the in vitro 
profiles of PDGF-BB release 
 Figure 3 shows the adsorption patterns of growth factors to gelatin hydrogel granules incorporating 
PGFM. For PRP treated with 0.8, 1, 2, and 4 wt% CaCl2 for 1 hr at 37 ℃, the amount of PDGF-BB 
adsorption was significantly low compared with that treated with 0.4 and 0.6 wt% CaCl2 (Figure 3A). The 
pattern of VEGF, EGF and TGF-β1 adsorption from the hydrogel granules incorporating PGFM was 
influenced by the CaCl2 concentration (Figures 3 B, C, and D). On the other hand, Figure 4 shows the 
adsorption patterns of growth factors to gelatin hydrogel granules incorporating mixed PGFM and bFGF 
and time courses of bFGF from gelatin hydrogel granules incorporating mixed PGFM and bFGF in PBS 
with or without collagenase. When mixed PGFM and bFGF were impregnated to gelatin hydrogel 
granules, the adsorption rate of bFGF to gelatin hydrogel granules was about 50 % of impregnated bFGF 
(Figure 4A). In the release in PBS, about 60 % of bFGF was released from the hydrogel granules. When 
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mixed PGFM and bFGF were impregnated to gelatin hydrogel granules, the initial burst of bFGF was 
increased compared with that of single impregnation of bFGF. However, when the release test was 
performed in PBS containing collagenase, the bFGF was release with time (Figure 4B). 
Figure 5 shows the time courses of PDGF-BB from gelatin hydrogel granules incorporating 
PRP treated with 2 wt% CaCl2 solution in PBS with or without collagenase. In the release in PBS, 
PDGF-BB was not released from the hydrogel granules, although the initial burst of small amount in 
release was observed. However, when the release test was performed in PBS containing collagenase, the 
PDGF-BB was release with time. The similar addition effect of collagenase on the time profile of 
hydrogel degradation was seen. A good correlation of time profiles was observed between the PDGF-BB 
release and the hydrogel degradation. 
 
Angiogenic effects of gelatin hydrogel granules incorporating mixed PGFM and bFGF 
Figure 6 shows the in vivo angiogenic effects of gelatin hydrogel granules incorporating 
PGFM with or without bFGF combination 1 week after implantation. The PRP was treated with 2 wt% 
CaCl2 solution. From the histological sections, the new formation of blood vessels was observed for the 
hydrogel granules incorporating mixed PGFM and bFGF. The number of blood vessels newly formed 
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was significantly high compared with that of other groups. The vessels number was not increased by 
injection of hydrogel granules incorporating PGFM, bFGF or PBS. PBS solution containing PGFM, 
bFGF or mixed PGFM and bFGF did not increase the number of new blood vessels (data not shown). The 
percentage of α-SMA-positive blood vessels increased by the granules incorporating mixed PGFM and 
bFGF to a significantly high extent compared with that of other controls. No difference in the vessels 
number between the right and left limbs was observed for the non-treated and empty granules injected 
groups. This indicates that neither the surgical procedure nor the granules injection induced angiogenesis.  
Figure 7 shows blood perfusion levels in the ischemic limb after the injection of different 
gelatin hydrogel granules incorporating mixed PGFM and bFGF. The injection of hydrogel granules 
incorporating mixed PGFM and bFGF significantly enhanced the perfusion index, in remarked contrast to 
that of other groups. 
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Discussion 
 The present study demonstrates that the multiple releases of PRP growth factors and bFGF 
from gelatin hydrogel granules was effective in increasing the number of blood vessels newly formed and 
the blood flow level in the ischemic legs. In addition, the number of α-SMA-positive blood vessels was 
also increased, which suggests the maturation enhancement of blood vessels. 
In the living tissue, it is well known that various growth factors interact with the components 
of extracellular matrix, such as acidic polysaccharides and collagen, through various intermolecular 
interaction forces [54]. In addition, the physicochemical interactions serve to maintain and enhance the in 
vivo biological function of growth factors. For instance, bFGF with an IEP of 9.6 forms polyion 
complexes with heparin and heparan sulfate in vivo, resulting in the stabilization and regulation of 
biological activities [43, 55]. The manner of natural physicochemical interactions is a good example to 
design the controlled release system of growth factors. Based on this, we have developed the 
biodegradable hydrogels of gelatin [9-11, 56]. The physicochemical property of gelatin, such as the 
electric nature, can be readily modified by the preparation procedure. For example, gelatin prepared with 
an alkaline process from collagen has an IEP of 5.0 and is negatively charged at the physiological pH, 
whereas an acidic process of collagen gives a positively charged gelatin with an IEP of 9.0. This electric 
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nature of gelatin can be used to interact electrostatically with growth factors of different IEPs [56]. 
Recently, human recombinant growth factors have become commercially available and have been 
experimentally or clinically used for tissue regeneration applications. However, only when the growth 
factor in the solution form is used in vivo, the biological activity is not always expected. This is because it 
is un-stable in vivo due to the rapid enzymatic digestion or deactivation. Therefore, their delivery 
technology is highly required to enable the growth factor to efficiently enhance the biological functions. 
We have succeeded in the controlled release of various growth factors as well as PRP from the gelatin 
hydrogels [6-13]. It has been recognized that when activated, the platelets of PRP release various growth 
factors through the degranulation of α granules and the factors released exhibit various biological 
activities [23]. For example, collagen and thrombin trigger the platelets aggregation and the subsequent 
release of platelet growth factors [57]. It is experimentally confirmed that the gelatin of a denatured 
collagen can function to trigger the platelet activation for growth factor release [36]. When impregnated 
into the hydrogel freeze-dried, it is likely that the PRP is activated by the contact with gelatin molecules 
to release the growth factors. The factors released interact with gelatin molecules during the impregnation 
procedure. Consequently, the PRP growth factors can be released from the gelatin hydrogels as a result of 
the hydrogel degradation. However, the contact of PRP with gelatin molecules is not always strong 
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enough to release out the PRP growth factors. In this study, the treatment of PRP with CaCl2 solution was 
tried to accelerate the release of PRP growth factors. The CaCl2 treatment is one of the well-known 
methods to activate PRP [41, 58].  
The adsorption experiment demonstrated that the percent of PRP growth factors desorbed 
increased with decrease in the CaCl2 concentration. This can be explained in terms of solution ionic 
strength. It is recognized that the growth factor physicochemically interacts with the gelatin molecules of 
hydrogels while one of the main interactions is the electrostatic. It is, therefore, likely that the increased 
CaCl2 concentration suppresses the interaction between the PRP growth factor and gelatin molecules, 
resulting in increased the desorption percentage. In addition, the pattern of PDGF-BB release from the 
hydrogel granules incorporating PGFM is influenced by the CaCl2 concentration. When the concentration 
was 4 wt%, higher amount of PDGF-BB release for the initial time period was observed compared with 
that of granules incorporating PGFM treated with 2 wt% CaCl2 solution. Taken together, the CaCl2 
concentration for PRP treatment was fixed at 2 wt%. The time profile of PDGF-BB release from the 
granules incorporating 2 wt% CaCl2 treated-PRP was in a good accordance with that of granules 
degradation. This indicates that the growth factor release is based on the degradation of release carrier 
hydrogels. When PRP treated with the freeze-and-thaw method, the concentration of PDGF-BB in the 
 24 
soluble fraction of PRP was significantly high compared with that of CaCl2-treated PRP. However, 
the activation of PRP by the freeze-and-thaw method is not always suitable because of the complicated 
process in clinic. 
The CaCl2 treatment affects the amount of platelet growth factor released and the adsorption 
profile to the hydrogel granules incorporating PGFM (Figures 1 and 2). In this study, PDGF-BB, VEGF, 
EGF, and TGF-β1 were selected as the representative platelet growth factor because of the high amount 
and the activity to enhance the maturation of blood vessels newly formed [47-49, 51, 53, 59]. In the CaCl2 
concentration of 1, 2, and 4 wt%, the amount of growth factors was higher than that of higher or lower 
CaCl2 concentrations. The treatment at the lower concentration would be not enough to activate the 
platelet. On the other hand, it is possible that the strong activation of platelet with CaCl2 solution of 
higher concentration results in the release out of platelet ingredients. The ingredients may suppress the 
activity of platelet growth factor. 
 We have demonstrated successful angiogenic effects on ischemic legs and hearts by 
biodegradable acidic gelatin hydrogels for the controlled release of bFGF [10, 11]. The bFGF release 
from the gelatin hydrogels was therapeutically effective in various animal models (i.e., either non-diabetic 
or diabetic) for acute myocardial infarction, prevascularization for cardiomyocyte transplantation to the 
 25 
ischemic heart, limb ischemia, and bone regeneration of sternum [14-21]. In the release system, both the 
biodegradable gelatin hydrogels of release carrier and the bFGF of an angiogenic factor are clinically 
available at present. Based on the results of animal experiments, several clinical trials have been started to 
confirm the safety and feasibility of bFGF release from the gelatin hydrogel in patients with clinical limb 
ischemia. The gelatin hydrogel for bFGF release is simple, safe, and effective from the clinical viewpoint. 
It is not necessary to use genetic materials and collect cells to be transplanted. In addition, no elevation of 
bFGF serum level was reported in the clinical case [22]. However, the bFGF release system has some 
rooms to be improved for the clinical applications. It is practically necessary for the treatment of patients 
with severe conditions to enhance the number of blood vessels newly formed and their biological 
maturation. The enhancement of blood vessels maturation is one of the practical strategies to treat such 
patients in the severe condition. There are several researches on the maturation of blood vessels in terms 
of growth factors usage. PRP is a source of autologous growth factors, including PDGF-BB, VEGF, EGF, 
and TGF-β. Several growth factors become intricately involved in angiogenesis. The PDGF-BB, VEGF, 
and TGF-β play an important role as proangiogenic stimulators. Several studies reported that PDGF-BB 
has a potent arteriogenic effect that promotes differentiation of endothelial cells [60], and VEGF is known 
to stimulate angiogenesis after ischemia [61], and TGF-β promote cell mitosis [53]. However, other 
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studies indicated that several growth factors, such as PDGF-BB and TGF-β, inhibit the angiogenic 
effect of bFGF [62-65]. These studies were evaluating the angiogenic effect using mixed solution of 
growth factors. Moreover, the amounts of growth factors was used transiently at high concentration. On 
the other hand, we used gelatin hydrogel granules incorporating PGFM and bFGF in this study, this 
gelatin hydrogel granules was degraded for 2 weeks, and sustained release the encapsulated growth 
factors. Thus, our sustained-release system and previous reports are fundamentally different. Among 
them, PDGF-BB is one of the powerful growth factors to allow the blood vessels to mature functionally 
[38, 49]. The finding gives us the idea that the multiple releases of PGFM and bFGF will enhance the 
maturation of blood vessels. Mooney et al. reported that the dual release of VEGF and PDGF enhanced 
the maturation of blood vessels newly formed compared with that of single VEGF release. The in vivo 
experiments clearly indicate that the dual release of PRP treated and bFGF from the biodegradable gelatin 
hydrogel granules promoted not only angiogenesis in a mouse model of limb ischemia, but also the 
maturation of blood vessels whereas the release of either PGFM or bFGF was not effective. There have 
been reported on the synergistic effects of different drugs on the enhancement of tissue regeneration 
[66-68] and tissue maturation. The dual release technology is available for any type of drug and to 
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Concentration of PDGF-BB released from PRP after the treatment of CaCl2 solution at different Ca2+ 
concentrations, the mixed solution of 2 wt% CaCl2 and thrombin, and freeze-and-thaw treated. *, p<0.05; 
significant different from the values of non-treated PRP. ✝, p<0.05; significant different from the values 




Concentration of growth factors released from PRP after the treatment of CaCl2 solution at different Ca2+ 
concentrations, the mixed solution of 2 wt% CaCl2 and thrombin, and freeze-and-thaw treated. (A) 
Concentration of EGF released from PRP. *, p<0.05; significant different from the values of non-treated 
PRP. ✝, p<0.05; significant different from the values of 10 wt% CaCl2-treated PRP. ‡, p<0.05; significant 
different from the values of freeze-and-thaw treated PRP. (B) Concentration of VEGF released from PRP. 
*, p<0.05; significant different from the values of freeze-and-thaw treated PRP. (C) Concentration of 




Adsorption of growth factors to gelatin hydrogel granules. After treatment of CaCl2 solution at different 
Ca2+ concentrations and the mixed solution of 2 wt% CaCl2 and thrombin, the PRP treated was 
incorporated into the gelatin hydrogels at 37 ℃ for 1 hr. The concentration of growth factors desorbed 
from gelatin hydrogel granules incorporating PGFM treated was detected by ELISA. (A) The percent 
adsorption of PDGF-BB to gelatin hydrogel. *, p<0.05; significant different from the values of 0.4 
wt%CaCl2 treated PRP. ✝, p<0.05; significant different from the values of 0.6 wt% CaCl2 treated PRP. ‡, 
p<0.05; significant different from the values of the mixed solution of 2 wt% CaCl2 and thrombin. (B) The 
percent adsorption of VEGF to gelatin hydrogel. (C) The percent adsorption of EGF to gelatin hydrogel. 
(D) The percent adsorption of TGF-β1 to gelatin hydrogel. 
 
Figure 4. 
Adsorption of bFGF to gelatin hydrogel granules and time course of bFGF release from gelatin hydrogel 
granules incorporating mixed PGFM and 125I-labeled bFGF. (A) The percent adsorption of bFGF to 
gelatin hydrogel. (B) The time course of bFGF release from gelatin hydrogel granules incorporating 
 42 
mixed PGFM and 125I-labeled bFGF (◯) and gelatin hydrogel granules incorporating 125I-labeled bFGF 
(●) in PBS with or without collagenase. The PBS solution was changed to that with collagenase at the 
time indicated with arrow. 
 
Figure 5. 
The time course of PDGF-BB release from gelatin hydrogel granules incorporating PRP treated with 2 
wt% CaCl2 solution (◯) and hydrogel degradation (●) in PBS with or without collagenase. The PBS 
solution was changed to that with collagenase at the time indicated with arrow.  
 
Figure 6. 
In vivo angiogenic effects of gelatin hydrogel granules incorporating PRP with or without bFGF 1 week 
after implantation. (A) Histological section ((a-f) hematoxylin and eosin and (g-l) anti-α-SMA 
immunohistochemical staining) of tissues injected with different gelatin hydrogel granules: (a, g) 
hydrogels incorporating PGFM and bFGF, (b, h) PGFM, (c, i) bFGF, (d, j) PPP or (e, k) PBS, and (f, l) 
non-treatment. The scale bar indicates 100 µm. (B) The number ratio of blood vessels newly formed 
around tissues injected with gelatin hydrogel granules. The number ratio of blood vessels newly formed 
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in the right (ischemic) limb was calculated as for that in the left (non-ischemic) limb of the same mouse. 
Ratio of 1.0 was calculated in non-treated mice. *, p<0.05; significant different from the value of gelatin 
hydrogel granules incorporating PPP. ✝, p<0.01; significant different from the value of gelatin hydrogel 
granules incorporating PBS. ‡, p<0.01; significant different from the value of non-treatment. (C) 
Percentage of anti-α-SMA antibody positive blood vessels around the tissue injected with gelatin 
hydrogel granules. The percentage of number of α-SMA-positive blood vessels to that of total blood 
vessels was calculated. *, p<0.05; significant different from the value of gelatin hydrogel granules 




In vivo blood perfusion effects of gelatin hydrogel granules incorporating PGFM with or without bFGF 1 
week after implantation. (A) Dorsal view of mouse image. The blood flow was measured in boxed area. 
(B) The image of laser Doppler perfusion of tissues injected with different gelatin hydrogel granules. (a) 
Hydrogels incorporating PGFM and bFGF, (b) PGFM, (c, i) bFGF, (d) PPP or (e) PBS, and (f) 
non-treatment. (C) The percentage of blood perfusion in the newly formed blood vessels around the tissue 
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injected with gelatin hydrogel granules. The percentage of blood perfusion in the right (ischemic) limb 
was calculated as for that in the left (non-ischemic) limb of the same mouse. The baseline is perfusion 
index of non-ischemic limb. 
 
 
 
 
 









